

參考文獻

1. Van Cutsem, J. The in-vitro antifungal spectrum of itraconazole. *Mycoses* **32 Suppl 1**, 7-13 (1989).
2. Heykants, J. et al, in: M.A. Fromtling (Ed.), Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents, J.R. Prous Science Publishers, Barcelona, 223 (1987).
3. Cauwenbergh, G. et al. Pharmacokinetic profile of orally administered itraconazole in human skin. *J Am Acad Dermatol* **18**, 263-8 (1988).
4. Phillips, P., Graybill, J. R., Fetchick, R. & Dunn, J. F. Adrenal response to corticotropin during therapy with itraconazole. *Antimicrob Agents Chemother* **31**, 647-9 (1987).
5. Koks, C. H., Sparidans, R. W., Lucassen, G., Crommentuyn, K. M. and Beijnen, J. H. Selective high-performance liquid chromatographic assay for itraconazole and hydroxyitraconazole in plasma from human immunodeficiency virus-infected patients. *J Chromatogr B Analyt Technol Biomed Life Sci* **767**, 103-10 (2002).
6. Compas, D., Touw, D. J. & de Goede, P. N. Rapid method for the analysis of itraconazole and hydroxyitraconazole in serum by high-performance liquid chromatography. *J Chromatogr B Biomed Appl* **687**, 453-6 (1996).
7. Heykants, J. et al. The clinical pharmacokinetics of itraconazole: an overview. *Mycoses* **32 Suppl 1**, 67-87 (1989).

8. Barone, J. A. et al. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. *Antimicrob Agents Chemother* **37**, 778-84 (1993).
9. Lim, S. G., Sawyerr, A. M., Hudson, M., Sercombe, J. & Pounder, R. E. Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity. *Aliment Pharmacol Ther* **7**, 317-21 (1993).
10. Hostetler, J. S. et al. Discrepancies in bioassay and chromatography determinations explained by metabolism of itraconazole to hydroxyitraconazole: studies of interpatient variations in concentrations. *Antimicrob Agents Chemother* **37**, 2224-7 (1993).
11. Warnock, D. W., Turner, A. & Burke, J. Comparison of high performance liquid chromatographic and microbiological methods for determination of itraconazole. *J Antimicrob Chemother* **21**, 93-100 (1988).
12. Law, D., Moore, C. B. & Denning, D. W. Bioassay for serum itraconazole concentrations using hydroxyitraconazole standards. *Antimicrob Agents Chemother* **38**, 1561-6 (1994).
13. Hulsewede, J. W., Dermoumi, H. & Ansorg, R. Determination of itraconazole and hydroxy-itraconazole in sera using high-performance-liquid-chromatography and a bioassay. *Zentralbl Bakteriol* **282**, 457-64 (1995).

14. Woestenborghs, R., Lorreyne, W. & Heykants, J. Determination of itraconazole in plasma and animal tissues by high-performance liquid chromatography. *J Chromatogr* **413**, 332-7 (1987).
15. Poirier, J. M., Lebot, M., Descamps, P., Levy, M. & Cheymol, G. Determination of itraconazole and its active metabolite in plasma by column liquid chromatography. *Ther Drug Monit* **16**, 596-601 (1994).
16. Perfect, J. R., Savani, D. V. & Durack, D. T. Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits. *Antimicrob Agents Chemother* **29**, 579-83 (1986).
17. Karel De Beule, Itraconazole : pharmacology, clinical experience and future development. *International Journal of Antimicrobial Agent* **6**,175-181 (1996).
18. Back, D. J. and Tjia, J. F. Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. *Br J Clin Pharmacol* **32**, 624-6 (1991).
19. Susan Budavari et al. The Merck Index 11 th, published by Merck & CO., INC. 5133 (1989).
20. Venkatakrishnan, K., von Moltke, L. L. & Greenblatt, D. J. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. *Clin Pharmacokinet* **38**, 111-80 (2000).

21. Marjorie A. Duffy et al. Physician's Desk Reference 27 th, published by Medical Economics, (2000).
22. De Beule, K. & Van Gestel, J. Pharmacology of itraconazole. *Drugs* **61 Suppl 1**, 27-37 (2001).
23. Espinel-Ingroff, A., Shadomy, S. & Gebhart, R. J. In vitro studies with R 51,211 (itraconazole). *Antimicrob Agents Chemother* **26**, 5-9 (1984).
24. Van Cutsem J. et al. The in vitro and in vivo antifungal activity of itraconazole. In Fromtling RA (Ed.) Recent trends in the discovery, development and evaluation of antifungal agents, JR Prous Science Publishers, S.A., 177-92 (1987c).
25. Yozwiak, M. L. & Galgiani, J. N. Itraconazole treatment of experimental systemic candidiasis in male rats. *J Med Vet Mycol* **25**, 125-6 (1987).
26. Van Cutsem J., Janssen PAJ. *In-vitro* and *in-vivo* models to study the activity of antifungals against *Aspergillus*. In Vanden Bossche H. et al. (Eds) *Aspergillus and aspergillosis*, Plenum Publishing Corporation, 215-27 (1988).
27. Van Cutsem, J., Van Gerven, F. & Janssen, P. A. Activity of orally, topically, and parenterally administered itraconazole in the treatment of superficial and deep mycoses: animal models. *Rev Infect Dis* **9 Suppl 1**, S15-32 (1987).

28. Longman, L. P. & Martin, M. V. A comparison of the efficacy of itraconazole, amphotericin B and 5-fluorocytosine in the treatment of *Aspergillus fumigatus* endocarditis in the rabbit. *J Antimicrob Chemother* **20**, 719-24 (1987).
29. Van Cutsem J. & Van Gerven F., Janssen PAJ. The *in vitro* evaluation of azoles. In Iwata K & Vanden Bossche H. (Eds) *In vitro* and *in vivo* evaluation of antifungal agents, Elsevier Science Publishers B.V. (Biomedical Division), 51-64 (1986).
30. Finkelievich, J. L., Negroni, R. & Arechavala, A. Treatment with itraconazole of experimental coccidioidomycosis in the Wistar rat. *Mycoses* **31**, 80-6 (1988).
31. McEwen, J. G. et al. Treatment of paracoccidioidomycosis with itraconazole in a murine model. *J Trop Med Hyg* **88**, 295-9 (1985).
32. Heykants J. et al. The pharmacokinetics of itraconazole in animals and man: an overview. Fromtling RA (Ed.) Recent trends in the discovery, development and evaluation of antifungal agents., JR Prous Science Publishers, S.A., 223-249 (1987).
33. Viviani, M. A., Tortorano, A. M., Woenstenborghs, R. & Cauwenbergh, G. Experience with itraconazole in deep mycoses in northern Italy. *Mykosen* **30**, 233-44 (1987).

34. Vanden Bossche, H. Biochemical targets for antifungal azole derivatives: hypothesis on the mode of action. *Curr Top Med Mycol* **1**, 313-51 (1985).
35. Gupta, A. K., Sauder, D. N. & Shear, N. H. Antifungal agents: an overview. Part II. *J Am Acad Dermatol* **30**, 911-33; quiz 934-6 (1994).
36. Vanden Bossche, H. et al. Mechanisms and clinical impact of antifungal drug resistance. *J Med Vet Mycol* **32 Suppl 1**, 189-202 (1994).
37. Powderly, W. G. Resistant candidiasis. *AIDS Res Hum Retroviruses* **10**, 925-9 (1994).
38. Ganger G. et al. Itraconazole solution in patients with non-response to fluconazole. PO-PB09, 9 th International Conference on AIDS, Berlin, June (1993).
39. Cartledge, J. D., Midgley, J., Youle, M. & Gazzard, B. G. Itraconazole cyclodextrin solution-effective treatment for HIV-related candidosis unresponsive to other azole therapy. *J Antimicrob Chemother* **33**, 1071-3 (1994).
40. Tucker, R. M. et al. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. *Clin Infect Dis* **14**, 165-74 (1992).
41. Bonay, M. et al. Possible interaction between phenobarbital, carbamazepine and itraconazole. *Drug Saf* **9**, 309-11 (1993).

42. Blomley, M., Teare, E. L., de Belder, A., Thway, Y. & Weston, M. Itraconazole and anti-tuberculosis drugs. *Lancet* **336**, 1255 (1990).
43. Pohjola-Sintonen, S., Viitasalo, M., Toivonen, L. & Neuvonen, P. Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. *Eur J Clin Pharmacol* **45**, 191-3 (1993).
44. Honig, P. K. et al. Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics. *J Clin Pharmacol* **33**, 1201-6 (1993).
45. Olkkola, K. T., Backman, J. T. & Neuvonen, P. J. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. *Clin Pharmacol Ther* **55**, 481-5 (1994).
46. Varhe, A., Olkkola, K. T. & Neuvonen, P. J. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. *Clin Pharmacol Ther* **56**, 601-7 (1994).
47. Yeh, J., Soo, S. C., Summerton, C. & Richardson, C. Potentiation of action of warfarin by itraconazole. *Bmj* **301**, 669 (1990).
48. Rex, J. Itraconazole-digoxin interaction. *Ann Intern Med* **116**, 525 (1992).
49. Kwan, J. T., Foxall, P. J., Davidson, D. G., Bending, M. R. & Eisinger, A. J. Interaction of cyclosporin and itraconazole. *Lancet* **2**, 282 (1987).

50. Tucker R. et al. The toxicity of itraconazole in 189 patients on chronic therapy. Proc 32th Annual Coccidioidomycosis Study Group Meeting, San Jose, CA, 8 April (1989).
51. Lavrijsen, A. P. et al. Hepatic injury associated with itraconazole. *Lancet* **340**, 251-2 (1992).
52. Tucker, R. M., Haq, Y., Denning, D. W. & Stevens, D. A. Adverse events associated with itraconazole in 189 patients on chronic therapy. *J Antimicrob Chemother* **26**, 561-6 (1990).
53. Hardin, T. C. et al. Pharmacokinetics of itraconazole following oral administration to normal volunteers. *Antimicrob Agents Chemother* **32**, 1310-3 (1988).
54. Barone, J. A. et al. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. *Antimicrob Agents Chemother* **37**, 778-84 (1993).
55. Wishart, J. M. The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection. *J Am Acad Dermatol* **17**, 220-3 (1987).
56. Haria, M., Bryson, H. M. & Goa, K. L. Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. *Drugs* **51**, 585-620 (1996).
57. Cauwenbergh, G. et al. Pharmacokinetic profile of orally administered itraconazole in human skin. *J Am Acad Dermatol* **18**, 263-8 (1988).

58. Cauwenbergh G. et al. Skin and tissue kinetics of itraconazole: a new triazole antifungal. 17th World Congress of Dermatology, Berlin (West), May 24-9 (1987).
59. Boelaert, J. et al. Itraconazole pharmacokinetics in patients with renal dysfunction. *Antimicrob Agents Chemother* **32**, 1595-7 (1988).
60. Van Peer, A., Woestenborghs, R., Heykants, J., Gasparini, R. & Gauwenbergh, G. The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects. *Eur J Clin Pharmacol* **36**, 423-6 (1989).
61. Heykants, J. et al: The pharmacokinetics of itraconazole in animals and man: an overview. In Fromtling RA (ed.) Recent trends in the discovery, development and evaluation of antifungal agents. Prous Science Publishers, Barcelona, 223-49 (1987).
62. Van Peer, A. et al. Determination of the oral bioavailability and bioequivalence of 100 mg of itraconazole from PEG- and pellet-capsule formulations with respect to a reference solution in man. Clinical Research Report, R 51211/73, Janssen Pharmaceutica, Beerse, Belgium (1987).
63. Wong, J. W., Nisar, U. R. & Yuen, K. H. Liquid chromatographic method for the determination of plasma itraconazole and its hydroxy metabolite in pharmacokinetic/bioavailability studies. *J Chromatogr B Analyt Technol Biomed Life Sci* **798**, 355-60 (2003).

64. Brandsteterova, E., Kubalec, P., Rady, A. & Krcmery, V. Determination of itraconazole and its metabolite in plasma using SPE-HPLC. *Pharmazie* **50**, 597-9 (1995).
65. Warnock, D. W., Turner, A. & Burke, J. Comparison of high performance liquid chromatographic and microbiological methods for determination of itraconazole. *J Antimicrob Chemother* **21**, 93-100 (1988).
66. Gubbins, P. O., Gurley, B. J. & Bowman, J. Rapid and sensitive high performance liquid chromatographic method for the determination of itraconazole and its hydroxy-metabolite in human serum. *J Pharm Biomed Anal* **16**, 1005-12 (1998).
67. Koks, C. H. et al. Population pharmacokinetics of itraconazole in Thai HIV-1-infected persons. *Ther Drug Monit* **25**, 229-33 (2003).
68. Cox, S. K., Orosz, S., Burnette, J. & Frazier, D. Microassay for determination of itraconazole and hydroxyitraconazole in plasma and tissue biopsies. *J Chromatogr B Biomed Sci Appl* **702**, 175-80 (1997).
69. Nakashima, K., Yamamoto, K., Al-Dirbashi, O. Y., Kaddoumi, A. & Nakashima, M. N. Semi-micro column HPLC of triazolam in rat plasma and brain microdialysate and its application to drug interaction study with itraconazole. *J Pharm Biomed Anal* **30**, 1809-16 (2003).

70. Kapsi, S. G. & Ayres, J. W. Processing factors in development of solid solution formulation of itraconazole for enhancement of drug dissolution and bioavailability. *Int J Pharm* **229**, 193-203 (2001).
71. Dupont, B. & E. Drouhet: Early experience with itraconazole *in vitro* and in patients: pharmacokinetic studies and clinical results. *Rev. Infect. Dis.* **9**, S43-6 (1978).
72. Warnock, D. W., Turner, A. & Burke, J. Comparison of high performance liquid chromatographic and microbiological methods for determination of itraconazole. *J Antimicrob Chemother* **21**, 93-100 (1988).
73. Chen Xiulan, Bai Lin, Lu Xiaochuan, Wang Xiaolei, Gao Cuiping. Serum and nail pharmacokinetic studies of itraconazole after multiple oral dosing to 9 healthy Chinese volunteers. *A cad J PLA Postgrad Med Sch* **19**, 265-7 (1998).